Presented on: June 26, 2020. 

Learning Outcome (s) 

1. Update on liver cancer statistics, standard therapies, novel developments and update on therapeutic algorithms
2. Learn about use of imaging and image-guided therapies to see, reach and treat liver cancer
3. Understand the use of Lipiodol as an Imaging Biomarker for Tumor Response

This webinar, by Dr. Julius Chapiro, will provide an update on liver cancer statistics, diagnostic and therapeutic algorithms and cover the currently approved indications for use of Lipiodol®  (Ethiodized Oil) Injection as an imaging biomarker for the therapy of liver cancer, discuss biological and physiological properties of Lipiodol, offer clinical and preclinical evidence for outcomes of liver-directed therapies with Lipiodol and provide an overview of applications for the use of Lipiodol as a marker for tumor necrosis and treatment response across multiple imaging modalities, including intra-procedural imaging.

About the Speaker - Julius Chapiro, MD

Dr. Chapiro is the Associate Research Scientist in Radiology and Biomedical Imaging at Yale School of Medicine. After graduating from the University of Leipzig and upon completion of his research thesis at the Justus-Liebig University in Giessen with summa cum laude, he served as a postdoctoral research fellow in interventional oncology at The Johns Hopkins Hospital and then as radiology resident at the Department of Radiology, Charité University Hospital in Berlin. Read his full profile here.

Brought to you by Guerbet

Guerbet has become one of the leading experts in medical imaging worldwide. Collectively, Guerbet offers a full range of medical solutions and services in diagnostic imaging and interventional imaging.

Accreditation Valid until June 23, 2022.